1Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atri- al fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTieoagulation and Risk Factors in Atri- al Fibrillation (ATRIA) Study [J]. JAMA, 2001,285(18) :2370- 2375.
2Wolf PA, D' Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study [ J ]. Stroke, 1991, 22(3) :312-318.
3De Caterina R, Husted S, Wallentin L, et al. New oral anticoagu- lants in atrial fibrillation and acute coronary syndromes: ESC Work- ing Group on Thrombosis-Task Force on Anticoagulants in Heart Dis- ease position paper [ J]. J Am Coil Cardiol, 2012, 59(16) :1413- 1425.
4Blech S, Ebner T, Ludwig-Sehwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [ J]. Drug Metab Dispos, 2008,36(2) :386-399.
5Giorgi MA, Cohen Arazi H, Gonzalez CD, et al. Changing anticoag- ulant paradigms for atrial fibrillation: dabigatran, apixaban and ri- varoxaban [ J]. Expert Opin Pharmaeother,2011,12(4) :567-577.
6Galanis T, Thomson L, Palladino M, et al. New oral anticoagulants [ J]. J Thromb Thrombolysis ,2011,31 ( 3 ) :310-320.
7Seaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists [ J ]. Clin Pharmacokinet,2013,52 ( 2 ) :69 -82.
8Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials [ J ]. Arch Intern Med,2012,172 (5) :397-402.
9Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med, 2011, 365 (10) :883-891.
10Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation [J]. N Engl J Med, 2011, 364(9) :806- 817.
